Related Experiment Video
Updated: May 28, 2025

09:45
Author Spotlight: Advancing Syphilis Research — Innovations in Treponema pallidum Cultivation and Genetic Engineering
Published on: January 24, 2025
2.9K
Procedures for In Vitro Cultivation of Treponema pallidum, the Syphilis Spirochete
Diane G Edmondson1, Steven J Norris2, Bridget D De Lay2
1University of Texas Health Science Center at Houston - McGovern Medical School; Diane.G.Edmondson@uth.tmc.edu.
Journal of Visualized Experiments : Jove
|February 10, 2025
Summary
Researchers have developed a new method for continuously culturing Treponema pallidum (syphilis bacterium) in vitro. This breakthrough enables new research into syphilis pathogenesis and treatment.
Area of Science:
- Microbiology
- Infectious Diseases
- Cell Biology
Background:
- Treponema pallidum subsp. pallidum, the causative agent of syphilis, has historically been difficult to culture in vitro.
- Previous propagation methods relied on animal models, limiting research.
- A breakthrough in 2018 enabled continuous in vitro cultivation.
Purpose of the Study:
- To detail the protocols for the in vitro cultivation of Treponema pallidum.
- To describe methods for maintaining necessary cell lines and generating isogenic strains.
- To facilitate further research into syphilis biology and treatment.
Main Methods:
- Co-culture of T. pallidum with rabbit epithelial cells (Sf1Ep cells).
- Utilizing a specialized tissue culture medium (TpCM-2) with serum.
- Culturing under specific conditions: 1.5% oxygen, 34 °C, with a 1-week passage time.
Main Results:
- Successful continuous in vitro cultivation of T. pallidum.
- T. pallidum doubling time in culture mirrors natural infection rates (33-45 hours).
- Established protocols for cell culture and strain generation.
Conclusions:
- The development of a reliable in vitro culture system for T. pallidum is a significant advancement.
- This system opens new experimental avenues for studying syphilis.
- Further research can now explore T. pallidum's biology and identify novel therapeutic targets.

